Xenetic Biosciences, Inc. (XBIO)
NASDAQ: XBIO · Real-Time Price · USD
2.800
-0.210 (-6.98%)
At close: Jun 18, 2026, 4:00 PM EDT
2.887
+0.087 (3.10%)
After-hours: Jun 18, 2026, 7:33 PM EDT
Xenetic Biosciences Revenue
Xenetic Biosciences had revenue of $806.92K in the quarter ending March 31, 2026, with 36.01% growth. This brings the company's revenue in the last twelve months to $3.19M, up 23.52% year-over-year. In the year 2025, Xenetic Biosciences had annual revenue of $2.98M with 19.04% growth.
Revenue (ttm)
$3.19M
Revenue Growth
+23.52%
P/S Ratio
2.01
Revenue / Employee
$1,595,037
Employees
2
Market Cap
6.41M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.98M | 476.13K | 19.04% |
| Dec 31, 2024 | 2.50M | -39.71K | -1.56% |
| Dec 31, 2023 | 2.54M | 833.06K | 48.80% |
| Dec 31, 2022 | 1.71M | 546.24K | 47.06% |
| Dec 31, 2021 | 1.16M | 723.75K | 165.64% |
| Dec 31, 2020 | 436.94K | 419.88K | 2,460.31% |
| Dec 31, 2019 | 17.07K | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | 7.59M | 4.59M | 152.83% |
| Dec 31, 2016 | 3.00M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 1.00M | 706.40K | 240.60% |
| Dec 31, 2012 | 293.60K | - | - |
| Aug 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Immuron | 4.99M |
| BioAtla | 2.00M |
| PMGC Holdings | 1.27M |
| Can-Fite BioPharma | 405.00K |
| AIM ImmunoTech | 94.00K |
| Silo Pharma | 72.10K |
XBIO News
- 17 days ago - Xenetic partner PeriNess receives Israeli MOH approval for DNase I study - TheFly
- 17 days ago - Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma - Accesswire
- 20 days ago - Xenetic announces preclinical data on DNase I at ASCO - TheFly
- 20 days ago - Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival - Accesswire
- 4 weeks ago - Xenetic Biosciences Slides: Investor presentation - Filings
- 5 weeks ago - Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform - Accesswire
- 5 weeks ago - Xenetic Biosciences Quarterly report: Q1 2026 - Filings
- 5 weeks ago - Xenetic Biosciences Earnings release: Q1 2026 - Filings